<DOC>
	<DOCNO>NCT00419484</DOCNO>
	<brief_summary>We want investigate effect pioglitazone cardiovascular event Japanese patient type 2 diabetes .</brief_summary>
	<brief_title>Effect Pioglitazone Cardiovascular Outcome Higashi-Saitama Trial Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Primary composite endpoint : Cardiovascular death Non-fatal myocardial infarction angina Non-fatal stroke Renal failure ( hemodialysis/doubling serum creatinine ) Secondary endpoint : urinary albumin excretion diabetic retinopathy hyperlipidemia hypertension gout</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>type 2 diabetes HbA1c : 7 % le 9 % insulin treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>